Satsuma Pharmaceuticals, Inc is a South San Francisco-based biopharmaceutical company that is currently in clinical-stage. They specialize in developing therapeutic products for the acute treatment of migraines and their lead product candidate is STS101, which is currently in SUMMIT Phase 3 efficacy trials. STS101 is unique in that it is a drug-device combination that utilizes a proprietary dry-powder formulation of dihydroergotamine mesylate and can be self-administered with a pre-filled, single-use, and nasal delivery device.